Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-Cigarette, or Vaping, Product Use-Associated Lung Injury – United States, November 2019

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Baldwin, Grant T. ; Briss, Peter A. ; Chatham-Stephens, Kevin ; Cho, Pyrone ; Delaney, Lisa J. ; Evans, Mary E. ; Glidden, Emily ; Jang, Yunho ; Jatalaoui, Tara C. ; Jones, Christopher M. ; Kabbani, Sarah ; King, Brian A. ; Ritchey, Matthew D. ; Roguski, Katherine ; Rose, Dale A. ; Trivers, Katrina F. ; Ussery, Emily N.
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.) Lung Injury Clinical Task Force ; Lung Injury Response Epidemiology/Surveillance Task Force
• Description:
  What is already known about this topic? A total of 2,172 e-cigarette, or vaping, product use-associated lung injury (EVALI) cases have been reported in the nationwide outbreak as of November 13, 2019; most patients reported using tetrahydrocannabinol-containing products in the 3 months before symptom onset. What is added by this report? As of November 5, 2019, 5% of EVALI patients were not hospitalized. Hospitalized and nonhospitalized patients had similar demographic and product use characteristics. What are the implications for public health practice? CDC will no longer collect national data on nonhospitalized EVALI cases. Further collection of data on nonhospitalized patients will be at the discretion of individual health departments. Clinical criteria are available to identify candidates for outpatient management of EVALI. Influenza vaccination should be considered for all persons who use e-cigarette, or vaping, products. [Description provided by NIOSH]
• Subjects:
  Communicable Diseases Demography Electrical Equipment And Supplies Hazardous Substances Influenza, Human Lung Lung Diseases Nicotine Occupational Health Public Health Respiratory System Respiratory Tract Diseases Safety Smokers Solvents Tobacco Products

  More +
• Keywords:
  Chemical Hazards Cigarette Smoking Data Processing Demographic Characteristics Disease Incidence Electronic Devices Hazardous Drugs Health Protection Humans Influenza Lung Disease Lung Disorders Medical Management Guidelines Medical Records Medical Treatment Outpatient Facilities Partnership Psychotropic Drugs Public Health Pulmonary Disorders Pulmonary Effects Pulmonary System Disorders Recordkeeping Safety Education Surveillance Tobacco Vaccines Vapors

  More +
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Publisher:
  Centers for Disease Control and Prevention (CDC) (U.S.)
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  United States
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  OD - Office of the Director
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  6 pdf pages
• Volume:
  68
• NIOSHTIC Number:
  nn:20057830
• Citation:
  MMWR 2019 Nov; 68(46):1076-1080
• Email:
  kchathamstephens@cdc.gov
• CAS Registry Number:
  (-)-Nicotine (CAS RN 54-11-5) ; Tetrahydrocannabinol (CAS RN 1972-08-3) ; Tobacco oil (CAS RN 8037-19-2)
• Federal Fiscal Year:
  2020
• Peer Reviewed:
  False
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR) National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:a1b45fecb12f7eed5de8cebab756f8ed646783acc4e70d2fe67051a111113cb21a0dd5d536cb8c2f3c012edaa28f1b50c79586a465dc2e92b258295ae2d4cec8
• Download URL:
  https://stacks.cdc.gov/view/cdc/183036/cdc_183036_DS1.pdf
• File Type:
  [PDF - 126.73 KB ]